Tue, Nov 10, 2026

PRAX is up 8.5% on a confirmed T1 SEC filing (8-K) with heavy volume. The position is profitable and has room to the 340 target. I am raising the stop to 320.00 (locked profit above the 15-min OR high of 289.50 and current VWAP area) to protect gains while letting the momentum run to the target. The news from Oppenheimer (Buy, PT $650) supports the bullish thesis but is not a reason to sell; it confirms the upside potential.

Triggered by our news engine: Oppenheimer Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $650 - Moomoo

USO is held in the Long-Term Book. The thesis is invalidation by a weekly close below the 200-day average. The current price (138.705) is well above the stop (115.75) and the 200-day average (implied ~120-125 range given 17.8% premium). The recent -3.55% move is an unexplained anomaly (T1 price/volume shock) with no fundamental catalyst in the last 24h. While caution is warranted, the long-term trend remains intact. No news has broken the trend. The stop is wide (17%+ below current price), providing ample room for volatility. Selling now on an unexplained drop would be premature unless a fundamental catalyst emerges. The position is up significantly over the last 12 months (107.8%), and the current drawdown is within normal bounds for a volatile asset like USO. No action is needed at this time.

PRAX is up 8.5% on strong FDA catalysts (Breakthrough Therapy, NDA extension). Price ($326) is well above the trailing stop ($310.39). The stop is already trailing at the initial entry distance (~$17 below entry). No new entry needed. Hold for target $340.

5 sh @ $325.83 · stop $310.39 · target $340.00

Price (139.88) remains above entry (136.96) and well above the stop (129.48). The earnings anticipation thesis is intact; the pullback from the 141.22 high is normal consolidation within the bounce. No news breaks the trend. Target 145 is still open.

Strongest setup: price above SMA20/50/200, positive 5d return, heavy volume breakout. Opening range low 22.66 provides tight stop. Reward 6% vs risk 4% (R:R > 1.2).

107 sh @ $23.57 ($2,521.99) · stop $22.66 · target $25.00

Good setup: price above SMA20/50/200, strong 5d/20d momentum, breakout on volume. RSI 75.4 is high but trend is strong. Opening range low 26.04 provides stop. Reward 5% vs risk 0.6% (R:R > 1.2).

4 sh @ $26.16 ($104.64) · stop $26.04 · target $27.50

MPC is a long-term leader held in the book. The recent price shocks (T1 anomalies) were minor dips absorbed by buyers, indicating resilience. The thesis relies on the long-term trend (price well above 200-day average) and the rule-managed stop at 312.05. No news breaks the long-term case. The current price action is within normal volatility for this stock. Hold as per book rules.

Triggered by our news engine: MPC +0.58% in 1 min (z 4.1 after removing SPY's move)

Price at 145.15 has moved well above entry (136.96). Trailing stop to lock in profits: entry minus original stop distance (136.96 - 129.47 = 7.49) gives a new stop at 137.66. This preserves the gain while letting the position run toward the 176.97 target. News remains skeptical (sentiment concerns, earnings preview), but price action is strong; the trail protects against a reversal.

4 sh @ $145.52 · stop $137.66 · target $176.97

PRAX is up 11.4% on strong Q3 results and a solid cash position ($1.3B). The move is backed by a confirmed T1 catalyst (SEC 8-K) and upcoming PDUFA dates in Dec '26/Jan '27. The position has exceeded its initial risk distance (entry 304.11 vs initial stop 281.67 = 22.44 risk). I am raising the stop to trail at that original distance (338.68 - 22.44 = 316.24) to lock in the majority of the gain while leaving room for the stock to run toward the 340 resistance level. No new entries are warranted at this stage; the thesis remains intact.

5 sh @ $338.21 · stop $316.24 · target $340.00

The position is a speculative bounce play in a strong daily downtrend (price 16% below SMA50, RSI 36.9). The thesis was that NBIS would bounce above its opening range on earnings anticipation. However, the stock has stalled and is now down -3.01% from the last review, failing to hold the gains. The trailing stop is at 137.66, and the current price of 141.31 is still above it, but the momentum has reversed. The news flow is negative: CoreWeave (a peer) faces sentiment issues, and NBIS earnings are imminent with high uncertainty (options pricing an 18% swing). In the closing window, intraday positions must be closed. The risk/reward is poor: the target of 145.00 is only 2.8% away, while the stop at 137.66 is 2.4% away, but the probability of hitting the target is low given the downtrend and lack of follow-through. Exiting now locks in the small profit and avoids the binary earnings risk.

4 sh @ $141.48 ($565.92)

U is in the TREND CORE, managed by rules that trail the stop and sell on a close below the 50-day average. The current price of 49.805 is above the trailing stop of 47.67. The recent news includes a BofA positive note and a consensus price target raise to $59.63, which supports the long-term thesis despite the intraday pullback. No news has broken the trend or invalidated the thesis. The rules will handle the exit if the stop is hit or the 50-day average is breached. I will not second-guess the price action or the rules-managed stop.

The position is held in the LONG-TERM BOOK, which normally requires a weekly close below the 200-day average to exit. However, the rules allow me to sell immediately on news that breaks the long-term case. The FDA's rejection of Optune Mya for lung cancer brain metastases is a massive negative catalyst (Severity 84) that fundamentally alters the growth trajectory and near-term visibility for RVMD's core pipeline. This is not a temporary dip; it is a structural impairment of the thesis. The stock is already down 4.56% on the news, confirming the market's negative assessment. Holding through this uncertainty violates the principle of acting when evidence gives an edge, as the risk of further downside is high and the upside is now capped by the rejected indication.

2 sh @ $190.97 ($381.94)

Triggered by our news engine: FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.